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Experimental Section

Methods
All reactions were carried out under an atmosphere of dry, oxygen-free nitrogen with dry and oxygen-free solvents using Schlenk line techniques. Molecular sieves (3 Å and 4 Å) were activated at 250 °C in vacuo for 3 h. Silica gel for inert column chromatography (Merck, 0.035-0.070 mm, 60 Å) was dried (with a heat gun) and degassed in vacuo for 6 h. Same silica gel was used for column chromatography in air. Biotage Isolera™ Four was used for flash column chromatography with the corresponding cartridges as indicated for each case. Thin-layer chromatography (TLC) was carried out on precoated glass plates (Merck Silica Gel 60 F254); visualization of the compounds on TLC plates was achieved by means of UV light (254 and 366 nm). Dry, oxygen-free tetrahydrofuran (THF), 1,2dimethoxyethane (DME) and 1,4-dioxane were distilled from sodium/benzophenone and stored over 4 Å molecular sieves. Dry, oxygen-free acetonitrile (MeCN) and dimethyl sulfoxide (DMSO) were distilled from CaH2 and stored over 3 Å (MeCN) or over 4 Å (DMSO) molecular sieves. Dry and oxygen-free N,N-dimethyl formamide (DMF), CH2Cl2 (DCM), diethyl ether (Et2O), n-hexane and toluene were obtained from an MBraun Solvent Purification System MB SPS-800, degassed and stored over 3 Å molecular sieves. For NMR measurements, CD2Cl2 (DCM-d2) and CDCl3 were dried by stirring at rt over P2O5 for 6 d, degassed by purging with nitrogen for 30 min under ultrasonic conditions and stored over 4 Å molecular sieves. Acetonitrile-d3 (CD3CN) was dried by stirring at rt over P2O5 for 4 d, followed by vacuum transfer into a storage flask. It was degassed by purging with nitrogen for 30 min applying ultrasonic conditions and stored over 3 Å molecular sieves. The same procedure was applied for DMSO-d6, but CaH2 was used instead as drying agent. Chemicals were used as purchased. Dulbecco`s phosphate saline buffer (PBS, 10 mM) was purchased from Biowest (w/o Mg and w/o Ca ions; Product Code: L0615) or freshly prepared in our laboratories according to the technical specification sheet from Dulbecco®. Magnesium-and fatty acids-free bovine serum albumin (BSAnoMg) was purchased from SERVA electrophoresis GmbH. The two reference compounds, namely ferrocifen (Fc-diOH) [1] and 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene (TAM-diOH), [2] were synthesized according to the literature. [NEt4][3-(η 3 -C3H5)-3-(CO)2-closo-3,1,2-MoC2B9H11] was synthesized as described elsewhere, [3] as well as 2-(tributylstannyl)pyridine [4] and [Pd(PPh3)4]. [5] 
Instrumentation
NMR spectra were acquired at room temperature with a Bruker AVANCE III HD 400 spectrometer. 1 H (400.13 MHz) and 13 C (100.16 MHz) NMR spectra were referenced to tetramethylsilane (TMS) as internal standard. 11 B (128.38 MHz) NMR spectra were referenced to the unified Ξ scale. [6] Mass spectrometry measurements were carried out in the ESI-MS mode using a Bruker ESQUIRE 3000 (Benchtop LC Iontrap) spectrometer. IR spectra were obtained with a PerkinElmer system 2000 FTIR spectrometer, scanning between 400 and 4000 cm −1 using KBr pellets, which were prepared in a glovebox under nitrogen atmosphere. Elemental analyses were performed with a Hereaus VARIO EL oven. The single crystal X-Ray data were collected on a Gemini-CCD diffractometer (RIGACU INC.) using Mo-Kα radiation (λ = 0.71073 Å), ω-scan rotation. Data reduction was performed with CrysAlis Pro [7] including the program SCALE3 ABSPACK [8] for empirical absorption correction. The structure solution for 6 and 9b was performed with SHELXT (dual-space method). [9] The graphical user interface ShelXle [10] was used for SHELXL. [11] The anisotropic full-matrix least-squares refinement on F 2 of all non-hydrogen atoms was performed with SHELXL-97. Except for disordered solvent molecules, all non-hydrogen atoms were refined with anisotropic thermal parameters and the HFIX command was used to locate all hydrogen atoms for non-disordered regions of the structure. The C2 unit within the carborane cluster was located with bond lengths analysis. Structure figures were generated with Mercury (version 4.0.0) [12] or UCSF Chimera (version 1.14). [13] CCDC-1944134 (6) and CCDC-1944251 (9b) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via https://summary.ccdc.cam.ac.uk/structure-summary-form (or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44)1223-336-033; or deposit@ccdc.cam.uk). UV-Vis absorption spectra were measured with a PerkinElmer UV/VIS/NIR Lambda 900 spectrometer, equipped with tungsten-halogen and deuterium lamps, using quartz cuvettes (V = 3 cm 3 , l = 10 mm). Spectra were recorded in the range 240-800 nm, at 1.0 nm resolution. Steady-state fluorescence emission and Rayleigh Light Scattering (RLS) spectra were measured with a PerkinElmer LS-50b spectrometer, equipped with a xenon-arc lamp, using quartz cuvettes (V = 1 cm 3 , l = 5 mm). Nanoparticle Tracking Analysis data were recorded using a NanoSight LM10 (Malvern Instruments Ltd, Worcestershire, UK), containing a sample chamber of about 0.25 mL, and equipped with a 532 nm-laser, a microscope LM14B and a camera sCMOS. The NTA 3.0 analytical software (NanoSight Ltd) was used for both capture and processing. Acquisition and processing parameters were optimized for each sample and the respective blank.
Syntheses
1-(2-Chloropyridin-4-yl)propan-1-one (2a)
The synthesis was done following Henegar et al. [14] In a Schlenk flask 2-chloroisonicotinic acid 1a (10.0 g, 63.4 mmol, 1.0 equiv.) was suspended in absolute THF (100 mL) and cooled to -40 °C. A solution of ethylmagnesium bromide in Et2O (3.0 M in Et2O, 63.5 mL, 190.5 mmol, 3.0 equiv.) was slowly added. The reaction mixture was slowly warmed to 0 °C and stirred at the same temperature for four hours. EtOAc (20 mL) followed by 6.0 M HClaq. (20 mL) were added to quench the reaction. The phases were separated, and the resulting aqueous phase was extracted with THF (3 x 30 mL). The combined organic phases were subsequently washed with 1.0 M NaOHaq. (2 x 20 mL) and brine (3 x 40 mL) and dried over MgSO4. The solvent was removed under reduced pressure and the crude mixture purified by flash column chromatography on silica with EtOAc/n-hexane 1:3 → 1:2 (v/v), to yield 2a (5.00 g, 29.5 mmol, 47%) as colorless crystals. 
RF (Hex
1-(2-Bromopyridin-4-yl)propan-1-one (2b)
2b was synthesized in an analogous manner as described for 2a, but using 2-bromoisonicotinic acid 1b (4.25 g, 20.9 mmol, 1.0 equiv.) and a solution of ethylmagnesium bromide in Et2O (3.0 M in Et2O, 25 mL, 62.5 mmol, 3.0 equiv.) in THF (100 mL). The product was purified as described for 2a, using EtOAc/n-hexane 1:3 → 1:2 (v/v), to yield 2b (1.86 g, 9.00 mmol, 43%) as colorless crystals. 
1-[(2,2'-Bipyridin)-4-yl]propan-1-one (3)
Method A (microwave reactions). 1-(2-Chloropyridin-4-yl)propan-1-one (2a) (50 mg, 0.29 mmol, 1.0 equiv.) was dissolved in absolute DMF (5 mL) and added to a mixture of [Pd(PPh3)4] (33.5 mg, 10 mol%), CuI (8.67 mg, 16 mol%) and 2-(tributylstannyl)pyridine (110 μL, 0.34 mmol, 1.2 equiv.). The reaction mixture was placed in a microwave reactor for 16 h at 140 °C. Then CsF (88 mg, 0.58 mmol, 2.0 equiv.) dissolved in distilled water (20 mL) was added to the reaction mixture and stirred for an hour at ambient temperature. The phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic phases were washed with H2O (10 mL) and brine (5 x 20 mL) until the remaining DMF was completely removed from the organic phase. The combined organic phases were dried over MgSO4, filtered and the solvent was removed under reduced pressure. Purification by flash column chromatography on silica gel (25 cm x 2 cm) using an EtOAc/nhexane 1:2 (v/v) with NEt3 (1%) eluent system yielded compound 3 (42 mg, 0.20 mmol, 69%).
Method B (reflux conditions). Alternatively, 1-(2-chloropyridin-4-yl)propan-1-one (2a) (2.46 g, 14.5 mmol, 1.0 equiv.) was dissolved in absolute DMF (ca. 75 mL) together with [Pd(PPh3)4] (1.68 g, 10 mol%), CuI (0.55 g, 20 mol%), CsF (4.84 g, 31.86 mmol, 2.2 equiv.). Then 2-(tributylstannyl)pyridine (5.1 mL, 15.95 mmol, 1.10 equiv.) was added via syringe and the reaction mixture was kept at 120 °C for 72 h. After cooling to ambient temperature, CH2Cl2 (50 mL) and H2O (50 mL) were added and the mixture filtered into a separation funnel to remove the formed solid. The same workup procedures were applied as for the microwave reaction adjusting solvent volumes accordingly. The crude mixture was purified by flash column chromatography using ISOLERA FOUR on silica gel (SNAP Ultra 100g) with an EtOAc/n-hexane 8% → 52% EtOAc (v/v) with NEt3 (1%) eluent system yielding 3 as a colorless solid (1.72 g, 8.10 mmol, 56%).
3 can be also synthesized with the same procedures but using 1-(2-bromopyridin-4-yl)propan-1one (2b) (62.1 mg, 0.29 mmol, 1.0 equiv.) and the other reagents and solvent volumes accordingly. Table S1 . Summary of the optimization process of the STILLE coupling reaction. All reactions were conducted in a total volume of solvent of 5 mL, with 0.29 mmol of 1-(2-X-pyridin-4-yl)propan-1-one (X = Cl, Br) and addition of CuI (16 mol% 
4-(1,1-Dibromobut-1-en-2yl)-2,2'-bipyridine (4a)
The synthesis was done following Fang et al. [15] P(Oi-Pr)3 (3.5 mL, 14.13 mmol, 3.0 equiv.) was added dropwise with a syringe at 0 °C to a solution of 3 (1.00 g, 4.71 mmol, 1.0 equiv.) and CBr4 (2.35 g, 7.07 mmol, 1.5 equiv.) dissolved in absolute CH2Cl2 (50 mL) (color changed from yellow to red). The mixture was allowed to slowly warm up to ambient temperature and stirred at 40 °C for four days. The yellow to brown reaction mixture was quenched with aq. saturated NaHCO3 solution (50 mL). The two phases were separated, and the aqueous phase was extracted with Et2O (3 x 30 mL). The combined organic phases were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The crude mixture was purified by flash column chromatography on silica gel (37 cm x 4 cm) with an EtOAc/n-hexane (1:3) with NEt3 (1%) eluent system yielding 4a as an off-white solid (1.35 g, 3.67 mmol, 78%). Recrystallization from hot n-hexane afforded 4a in high purity as colorless crystals. 
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4-(1,1-Dichlorobut-1-en-2yl)-2,2'-bipyridine (4b)
The synthesis was done following Kumar et al. [16] PPh3 (1.48 g, 5.65 mmol, 6.0 equiv.) in absolute toluene (15 mL) CCl4 (0.28 mL, 2.83 mmol, 3.0 equiv.) was added with a syringe to a solution of 3 (0.20 g, 0.94 mmol, 1.0 equiv.). The reaction mixture was stirred at 110 °C for three days. After cooling to rt the mixture was diluted with CH2Cl2 and exposed to air. The solvent was removed under reduced pressure and the crude product was loaded on silica gel to perform column chromatography (ISOLERA ONE) using a gradient of 6% → 50% EtOAc (v/v) with NEt3 (1%) resulting in 4b as an offwhite solid (0.14 g, 0.64 mmol, 68%). Recrystallization from hot n-hexane did not afford complete separation of the joint product, namely P(O)Ph3, from 4b. However, the identified impurity does not disturb the next reaction step. 07 mmol, 10 mol%) were dissolved in distilled 1,4-dioxane (16 mL) and degassed, distilled water (4 mL) and stirred at 100 °C for four days. Ethylacetate (EtOAc; 20 mL) and H2O (20 mL) were added to the orange reaction mixture. The two phases were separated, and the aqueous phase extracted with EtOAc (3 x 20 mL). All combined organic phases were washed with brine (3 x 25 mL) and dried over MgSO4, filtered, and the solvent removed under reduced pressure. The crude mixture was purified by flash column chromatography using ISOLERA FOUR on silica gel (SNAP Ultra 25g) with an EtOAc/n-hexane 2% → 20% EtOAc (v/v) with NEt3 (3%) eluent system yielding 5 as colorless solid (0.23 g, 0.54 mmol, 73%). Larger scale: 4a (1.00 g, 2.71 mmol), yield: 5 (0.75 g, 65%). Table S2 . Summary of the optimization process of the Suzuki coupling reaction. All reactions were conducted in a total solvent volume of 10 mL, with 0.065 mmol of 5 (1.0 equiv.) and 4-methoxyphenylboronic acid (0.26 mmol, 4.0 equiv.).
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Catalyst 
4-[1,1-Bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6)
In a Schlenk flask 5 (0.180 g, 0.456 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (10 mL) and cooled to -65 °C. BBr3 (0.26 mL, 2.74 mmol, 6.0 equiv.) was added slowly to the mixture via syringe and the mixture was slowly warmed up to ambient temperature and then stirred for 12 h (the color of the reaction mixture changed from orange/red to light orange and the formation of a precipitate was observed). The reaction was quenched with H2O (20 mL), the two phases were separated, and the aqueous phase was extracted with EtOAc (3 x 20 mL). All combined organic phases were dried over MgSO4, filtered and the solvent was removed under reduced pressure. Flash column chromatography on silica gel (22 cm x 3 cm) using a CHCl3/MeOH/NH3(aq.) 8:1:0.1 (v/v) eluent system yielded a paleyellow sticky solid, which was recrystallized from hot CHCl3 with a few drops of MeOH to give pale yellow crystals of 6 (0.143 g, 80%). 
[3,3-{1-[(2,2'-Bipyridin-κ 2 N,N')-4-yl]propan-1-one}-3-(CO)2-closo-3,1,2-MoC2B9H11] (8)
A stock solution of [NEt4][3-(η 3 -C3H5)-3-(CO)2-closo-3,1,2-MoC2B9H11] (7) (7.5 mL, 1.49 mmol, 1.0 equiv.) in THF (0.2 M) was treated with HCl in Et2O (2 M in Et2O, 1.1 mL, 2.24 mmol, 1.5 equiv.) at 0 °C and the mixture was stirred for 30 min at the same temperature, and then for 30 min at rt. 4 (0.317 g, 1.49 mmol, 1.0 equiv.) dissolved in THF (5 mL) was then added to the green reaction mixture and then stirred at 50 °C for 16 h (color change to purple). The solvent was removed under reduced pressure and the residue dried in vacuum for 1 h. The crude residue was exposed to air and purified by flash column chromatography (applying N2 gas) on silica gel (29 cm x 4 cm) using pure CH2Cl2 as eluent. The third violet band (RF (CH2Cl2) = 0.6) was collected yielding 8 as a dark violet solid (0.136 g, 18%). 
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[3,3-{4-[1,1-Bis(4-methoxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ 2 N,N'}-3-(CO)2-closo-3,1,2-MoC2B9H11] (9)
The same procedure was applied as for 8, but using [NEt4][3-(η 3 -C3H5)-3-(CO)2-closo-3,1,2-MoC2B9H11] (7) (5.0 mL, 1.00 mmol, 1.0 equiv.) in THF (0.2 M), HCl in Et2O (2 M in Et2O, 0.75 mL, 1.50 mmol, 1.5 equiv.) and 5 (0.423 g, 1.00 mmol, 1.0 equiv.). Flash column chromatography (applying N2 gas) was performed on silica gel (36 cm x 4 cm) using CH2Cl2/n-hexane (8:1) → CH2Cl2. The first violet band was collected (RF (CH2Cl2): 0.8) yielding 9 as a dark violet solid (0.140 g, 20%). Additionally, the second violet band (RF (CH2Cl2): 0.67) was collected and could be identified as the B(8)-substituted chloro derivative (9b). [3,3-{4-[1,1-Bis(4-methoxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ 2 N,N'}-3-(CO)2-8-chloro-closo-3,1,2-MoC2B9H11 -κ 2 N,N'}-3-(CO)2-closo-3,1,2 -MoC2B9H11] (10) The same procedure was applied as for 8, but using CCDC-1944134 (6) and CCDC-1944251 (9b) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk. Figure S1 . Packing of 6 in the solid state stabilized by intermolecular hydrogen bonds. The thermal ellipsoids are presented at 30% probability level and the hydrogen atoms not involved in hydrogen bonds are omitted for clarity. One molecule of 6 is highlighted. Figure S2 . Molecular structures of the two isomers of 9b in the solid state (not the packing in the crystal is shown here). Thermal ellipsoids are presented at 50% probability level and hydrogen atoms are omitted for clarity. CCDC number 1944251.
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[3,3-{4-[1,1-Bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine
X-ray Crystallography
Stability and Solution Behavior Studies
NMR Spectroscopy
In the 1 H NMR spectra of the ligands alone (3, 5 and 6) compared to the chemical shifts in complexes 8, 9 and 10, there is a clear coordination shift detectable ( Figures S3−S5) . The CHcluster signals split into two broad singlets due to the non-symmetric N,N-chelating ligand. Importantly, the coordination of 3, 5 and 6 at molybdenum(II) generates always two isomers, which cannot be distinguished via NMR spectroscopy. The carbonyl groups give two slightly different signals at 255.3 and 254.5 ppm (8, CD2Cl2), 256.3 and 255.5 ppm (9, CDCl3) or 260.3 and 260.0 ppm (10, CD3CN) in the 13 C{ 1 H} NMR spectra of the respective complexes according to the C1 symmetry of the whole molecule.
For in vitro cell culture tests, the stock solutions of sparingly water-soluble compounds are typically prepared in DMSO (ethanol or methanol are good alternatives) and stored below 4 °C. For that purpose, the chemical stability of 3, 5, 6 and 8−10 was tested in a solution of water-containing DMSO-d6 in air for at least 36 days (3, 5, 6, 8, 9 ) and for 14 days for complex 10. In all cases, 1 H and 11 B{ 1 H} NMR spectra, where appropriate, revealed that the ligands 3, 5 and 6 can be stored in a DMSO stock solution for at least a month without decomposition, and the molybdacarboranes for 14 days up to a month with minor decomposition (where the decomposition products are the free ligands 3, 5 or 6, the nido-ortho-carborane ([nido-C2B9H12] − ) and most likely a molybdenum species in higher oxidation state) (see Figures S6−S14). S14. Stability test for 10 in DMSO-d6 stock solution via 11 B{ 1 H} NMR spectroscopy, over 14 days. Minor changes could be detected. The slowly growing broad peak at ca. 20 ppm is due to agglomeration and the changes observed are not related to decomposition, but rather to reorganization of the molecules in solution.
UV-Vis, Fluorescence and Resonance Light Scattering (RLS) Spectroscopy
All working solutions were kept at a controlled temperature of 25 °C for the whole duration of the experiments. UV-Vis spectra were recorded at 25 °C, in the range of 190-800 nm, at 1.0 nm resolution. All measurements were corrected by subtracting the respective blank: PBS + 2.0 vol% DMSO for measurements in buffer. Fluorescence emission spectra were acquired in the range 290-550 nm, with cut-off (emission) filter at 290 nm. Three excitation wavelengths (λexc) were used, λ280 (Trp and Tyr), λ295 (Trp) and λ320 (reference λexc for [BSAnoMg-warfarin] complex), with excitation and emission slits of 5.0 and 2.5 (λ280), 2.5 and 2.5 (λ295), 5.0 and 2.5 (λ320) nm, respectively. Each measurement was corrected subtracting the blank (PBS + 2 vol% DMSO) at the respective λexc. Raw data (number of scans = 3) were smoothed with 10 points moving average function, integrated in the software FLWINLab. The two-and three-components systems, i.e. [BSAnoMg-6/10], [BSAnoMgsite marker], [BSAnoMg-site marker-6/10] and [BSAnoMg-6/10-site marker], as well as the respective reference solutions were measured over 24 h with UV-Vis and fluorescence spectroscopy (spectra see Figure S15 −S16). RLS spectra were measured after 1 h from sample preparation and were acquired with Δλ = λem -λexc = 0 nm, as reported, [17] closed slits, and 1% transmittance attenuator filter. Each measurement was corrected subtracting the blank (PBS + 2 vol% DMSO). Raw data (ns = 3) were smoothed with 10 points moving average function, integrated in the software FLWINLab. 10 1) . In contrast, for 10, no improvement of the solubility could be detected as formulated with BSAnoMg (1:1), the RLS intensity even increases. The blanks consist of PBS + 2% DMSO.
Nanoparticle Tracking Analysis (NTA)
The possible self-assembling behavior of 6 and 10 in PBS/DMSO mixture (pH 7.4) was analyzed by Nanoparticle Tracking Analysis (NTA), with and without BSAnoMg, applying an analogous procedure as reported previously. [18] Samples of 6 and 10 in PBS/DMSO were prepared as described for UV-Vis, fluorescence and RLS measurements and measured 0. Figure S18 . ESI high-resolution mass spectrum (neg.) of 10 showing the agglomeration taking place in solution (here: CH3CN/CD3CN). In order to draw interferences between the activity of the novel molecules, which are inspired by tamoxifen, a drug for hormone-dependent breast cancer treatment, and the presence of the ER receptors, the receptor status for ER-α and ER-β was tested. This is reasonable, due to the fact that the two transcriptions factors (ER-α and ER-β) have a very important role in health and disease, and the real ER status of the tested cell lines should always be doublechecked to draw a connection to the tested compounds. [19] Therefore, bridging the gap between the tested cell lines and the estrogen receptors alpha (ER-α) and beta (ER-β), western blot analysis was performed ( Figure S21) . It revealed that the tested cell lines express the ER-α -MDA-MB-361, MCF-7 and LN-229 in higher amounts, MDA-MB-231 in medium amounts and U-251 to a lesser extent. Concerning the expression of the ER-β, also all cell lines express this receptor, but to varying extent. MDA-MB-231 and U-251 show low expression of ERβ, whereas MDA-MB-361, MCF-7 and LN-229 express higher amounts of ER-β. Vivid discussion is found in the literature about the validity of the commercially available ER-α/ER-β antibodies: their selective binding is doubted, and in turn, the estrogen receptor status of the cells is found to be contradicting throughout the literature. [20] However, it seems that the anticancer potential of our newly designed compounds is not in correlation with ER receptor expression, under the applied concentrations, indicating the existence of other targets for these molecules. 
Mass Spectrometry
Biological Studies
